'%2F%3E%3Cpath%20d%3D'M11%205H21M13.5%205V11.6A8.5%208.5%200%201%200%2018.5%2011.6V5'%20fill%3D'none'%20stroke%3D'%23fff'%20stroke-width%3D'3.4'%20stroke-linecap%3D'round'%20stroke-linejoin%3D'round'%2F%3E%3Cpath%20d%3D'M10.6%2019.6L13.9%2021.8L17.6%2018.4L21.4%2020.4'%20fill%3D'none'%20stroke%3D'%23fff'%20stroke-width%3D'2.6'%20stroke-linecap%3D'round'%20stroke-linejoin%3D'round'%2F%3E%3Ccircle%20cx%3D'17.6'%20cy%3D'18.4'%20r%3D'2.6'%20fill%3D'%23fff'%2F%3E%3C%2Fsvg%3E){kind=small}
ANG Lifesciences India Limited
ANG (BSE 540694) · ISIN INE236W01016 · Pharmaceuticals · Est. 2006 · listed 2017 · website
Not on any surveillance list
Open the full company file Every section, filings and your notes, in the app.
Quarterly results
No quarterly results stored for this company yet.
Balance sheet
| As of | Total equity | Borrowings | Total assets |
|---|---|---|---|
| 31 Mar 2026 standalone | ₹62.22 cr | ₹64.97 cr | ₹189.91 cr |
| 30 Sep 2025 standalone | ₹65.26 cr | ₹75.79 cr | ₹224.06 cr |
| 31 Mar 2025 standalone | ₹66.81 cr | ₹67.8 cr | ₹208.67 cr |
Shareholding
| Promoter | FII | DII | Public |
|---|---|---|---|
| 70.60% | — | — | 29.40% |
Latest filings
- Annual Report FY2025-26 (New) 7 September 2026 · BSE
- Financial Results 30.06.2026. 14 August 2026 · BSE
- Submission of standalone and consolidated unaudited financial results for the quarter ended on 30.06.2026 under Regulation 33 of the SEBI (LODR) Regulations, 2015 14 August 2026 · BSE
- Audited Results 31.03.2026 30 May 2026 · BSE
- Audited Financial Results for the quarter and year ended 31st March, 2026 30 May 2026 · BSE
Other companies in Pharmaceuticals
- Lupin Limited
- Sun Pharmaceutical Industries Limited
- Torrent Pharmaceuticals Limited
- Zydus Lifesciences Limited
- Ajanta Pharma Limited
- Alivus Life Sciences Limited
- Wockhardt Limited
- Morepen Laboratories Limited
Figures as filed by the company with NSE and BSE; surveillance status from the exchanges' lists. Updated 30 September 2026.
Information and calculation tools by Rachid Asen. Not investment advice or research. Facts from company filings and the exchanges' lists, for information only; not a recommendation to buy, sell or hold. Verify with the exchange.